Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22011232 | 0.92 | MAPT (0.32) | HTR2ASSTR5MAPTRXFP1 | |
| SCHEMBL22011216 | 0.89 | MAPT (0.30) | HTR2AMAPT | |
| SCHEMBL22010982 | 0.88 | CNR2 (0.36) | HTR2AALDH1A1MAPTHTTCNR1 | |
| SCHEMBL22011792 | 0.86 | SCN9A (0.33) | HTR2AMAPT | |
| SCHEMBL22011211 | 0.86 | CNR2 (0.34) | ALDH1A1MAPTHTTCNR1CNR2 | |
| SCHEMBL22010814 | 0.85 | SSTR5 (0.33) | HTR2ASSTR5ALDH1A1RXFP1 | |
| SCHEMBL22011195 | 0.84 | SCN9A (0.39) | HTR2AALDH1A1CNR2 | |
| SCHEMBL22010818 | 0.83 | — | — | |
| SCHEMBL22010806 | 0.82 | SSTR5 (0.32) | HTR2ASSTR5RXFP1 | |
| SCHEMBL22010805 | 0.82 | CYP2C9 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | YBX1, ZKSCAN2, RCC1 | HTR2A 1052/4885SSTR5 2260/4885ALDH1A1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.